Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca’s lupus drug anifrolumab fails in Tulip 1 phase III trial
Image: The lupus drug anifrolumab has failed to meet primary endpoint in Tulip 1 phase III trial. Photo: courtesy of AstraZeneca.
Image: The lupus drug anifrolumab has failed to meet primary endpoint in Tulip 1 phase III trial. Photo: courtesy of AstraZeneca.